Macquarie Group LTD Relmada Therapeutics, Inc. Transaction History

Macquarie Group LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$3.1 - $6.8 $2,653 - $5,820	856 New	856 $3,000
Q3 2022 Nov 14, 2022	SELL	$18.3 - $37.02 $2,122 - $4,294	-116 Closed	0 $4,000
Q1 2021 May 14, 2021	SELL	$31.52 - $39.28 $1,733 - $2,160	-55 Reduced 32.16%	116 $4,000
Q2 2020 Aug 11, 2020	SELL	$31.59 - $49.98 $85,450 - $135,195	-2,705 Reduced 94.05%	171 $8,000
Q1 2020 May 15, 2020	BUY	$23.78 - $50.12 $68,391 - $144,145	2,876 New	2,876 $98,000

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.9M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.